The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial.
The efficacy of curcumin-piperine co-supplementation on clinical symptoms, duration, severity, and inflammatory factors in COVID-19 outpatients: a randomized double-blind, placebo-controlled trial.
复制标题
联合补充姜黄素和胡椒碱对新冠肺炎门诊患者临床症状、持续时间、严重程度和炎症因子的疗效：一项随机、双盲、安慰剂对照试验。
DOI：
10.1186/s13063-022-06375-w
复制
发表时间：
2022-06-06
期刊：
影响因子：
2.5
通讯作者：
Bagherniya, Mohammad
中科院分区：
文献类型：
--
作者：
Askari, Gholamreza;Sahebkar, Amirhossein;Soleimani, Davood;Mahdavi, Atena;Rafiee, Sahar;Majeed, Muhammed;Khorvash, Farzin;Iraj, Bijan;Elyasi, Mahshid;Rouhani, Mohammad Hossein;Bagherniya, Mohammad
COVID-19 pandemic has made the disease a major global problem by creating a significant burden on health, economic, and social status. To date, there are no effective and approved medications for this disease. Curcumin as an anti-inflammatory agent can have a positive effect on the control of COVID-19 complications. This study aimed to assess the efficacy of curcumin-piperine supplementation on clinical symptoms, duration, severity, and inflammatory factors in patients with COVID-19. Forty-six outpatients with COVID-19 disease were randomly allocated to receive two capsules of curcumin-piperine; each capsule contained 500 mg curcumin plus 5 mg piperine or placebo for 14 days. Mean changes in complete blood count, liver enzymes, blood glucose levels, lipid parameters, kidney function, and c-reactive protein (CRP) were not significantly different between the two groups. There was a significant improvement in health status, including dry cough, sputum cough, ague, sore throat, weakness, muscular pain, headache, and dyspnea at week 2 in both curcumin-piperine and placebo groups (P value < 0.05); however, the improvement in weakness was more in the curcumin-piperine group than with placebo group (P value 025). The present study results showed that curcumin-piperine co-supplementation in outpatients with COVID-19 could significantly reduce weakness. However, in this study, curcumin-piperine co-supplementation could not significantly affect the other indices, including biochemical and clinical indices. Iranian Registry of Clinical Trials IRCT20121216011763N46. 2020-10-31
登录
查看更多内容
影响因子：
11.4
作者：
Chin D;Huebbe P;Frank J;Rimbach G;Pallauf K
通讯作者：
Pallauf K
影响因子：
3.6
作者：
Bhutani, Whit Kumar;Bishnoi, Mahendra;Kulkarni, Shrinivas K.
通讯作者：
Kulkarni, Shrinivas K.
影响因子：
4.2
作者：
Hong, Namki;Kim, Chang Oh;Rhee, Yumie
通讯作者：
Rhee, Yumie
影响因子：
7.2
作者：
Hassaniazad, Mehdi;Eftekhar, Ebrahim;Nikpoor, Amin Reza
通讯作者：
Nikpoor, Amin Reza
姜黄素（姜黄的组成部分）：针对Covid-19的新治疗选择。
影响因子：
3.9
作者：
Babaei F;Nassiri-Asl M;Hosseinzadeh H
通讯作者：
Hosseinzadeh H